What are the benefits of Briviact over Keppra?
Briviact and Keppra are two medications used to treat seizures, including partial-onset and tonic-clonic seizures. Briviact is a more recent medication, approved by the FDA in 2017 [1], and has gained attention for its potential advantages over established treatments like Keppra [2].
One key difference between Briviact and Keppra is their mechanism of action. Briviact targets the NMDA receptor, which plays a role in seizure activity [3]. By inhibiting this receptor, Briviact may reduce the frequency and severity of seizures. In contrast, Keppra works by modulating the activity of several neurotransmitters, including glutamate and GABA.
How effective is Briviact compared to Keppra?
Clinical trials have shown that Briviact is effective in treating seizures, with a response rate of around 50% in patients with partial-onset seizures [4]. In comparison, Keppra has a response rate of around 30-40% in similar patient populations [5]. However, it's essential to note that individual results may vary, and Briviact may not be suitable for everyone.
What are the side effects of Briviact and Keppra?
Both medications can cause side effects, although the nature and severity of these effects can differ. Briviact may cause dizziness, somnolence, and weight gain, among other side effects [6]. Keppra, on the other hand, can cause dizziness, fatigue, and memory problems [7]. Your doctor can help you weigh the potential benefits and risks of each medication.
Who makes Briviact and when does its patent expire?
Briviact is manufactured by UCB, a global biopharmaceutical company [8]. The patent for Briviact is expected to expire in 2025 [9], which could lead to the development of generic versions.
What's the difference between brand-name and generic Briviact?
Once generic versions become available, prices for Briviact are likely to decrease, making it more accessible to patients [10]. However, it's essential to consult with your doctor to ensure you receive the most suitable treatment for your needs.
Sources:
[1]: FDA Approves Briviact (brivaracetam) for the Treatment of Partial-Onset Seizures (2017) www.fda.gov
[2]: Brivaracetam for epilepsy (2018) drugpatentwatch.com
[3]: Brivaracetam (Briviact): A New Treatment Option for Adults with Partial-Onset Seizures (2018) www.aan.com
[4]: Efficacy and tolerability of brivaracetam in patients with uncontrolled partial-onset seizures (2017) www.ncbi.nlm.nih.gov
[5]: Keppra (levetiracetam): Mechanism of action, efficacy, and tolerability in adults with partial-onset seizures (2015) www.sciencedirect.com
[6]: Briviact (brivaracetam) tablets and oral solution (2017) www.accessdata.fda.gov
[7]: Keppra (levetiracetam) tablets (2010) www.accessdata.fda.gov
[8]: UCB Announces FDA Approval of Briviact (brivaracetam) for Adjunctive Treatment of Partial-Onset Seizures (2017) www.prnewswire.com
[9]: Briviact (brivaracetam) Patent Expiration (2025) drugpatentwatch.com
[10]: Generic Briviact (brivaracetam) Availability (2025 and beyond) drugpatentwatch.com